Combination Treatment With VELCADE and Low-Dose Tissue Plasminogen Activator Provides Potent Neuroprotection in Aged Rats After Embolic Focal Ischemia | Zendy

Li Zhang | Zendy; Zheng Gang Zhang | Zendy; Ben Buller | Zendy; James Jiang | Zendy; Yanting Jiang | Zendy; Danping Zhao | Zendy; Xianshuang Liu | Zendy; Dan Morris | Zendy; Michael Chopp | Zendy

Open Access

Combination Treatment With VELCADE and Low-Dose Tissue Plasminogen Activator Provides Potent Neuroprotection in Aged Rats After Embolic Focal Ischemia

Author(s) -

Li Zhang,

Zheng Gang Zhang,

Ben Buller,

James Jiang,

Yanting Jiang,

Danping Zhao,

Xianshuang Liu,

Dan Morris,

Michael Chopp

Publication year - 2010

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.577288

Subject(s) - medicine , neuroprotection , ischemia , tissue plasminogen activator , stroke (engine) , t plasminogen activator , pharmacology , ischemic stroke , brain ischemia , fibrinolytic agent , mechanical engineering , engineering

Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study investigated the effect of VELCADE in combination with a low-dose tPA on aged rats after embolic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research